<?xml version="1.0" encoding="UTF-8"?><protocol_summary><protocol><id>16359</id><no>SUPERNUS-ONAPGO-830P401</no><status>Open</status><title>Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease</title><secondary_protocol_no>830P401</secondary_protocol_no><nct_id>NCT00000000</nct_id><sponsor_type>Industrial</sponsor_type><age_group>Adult</age_group><treatment_type>Observational</treatment_type><phase>IV</phase><disease_site>Other</disease_site><PI>Pagan, Fernando</PI><institution>Georgetown University Medical Center; Lombardi Comprehensive Cancer Center</institution><management_group>GUMC Neurology</management_group></protocol><sipVersion>2026.1.0 Build 16</sipVersion><copyright> &lt;a href="https://advarra.com" target="_blank"&gt;&amp;copy; 2026 Advarra, Inc.&lt;/a&gt; </copyright></protocol_summary>